Product Details
Xeomin is indicated for temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. Xeomin can help differentiate your practice. Xeomin is different in ways that matter to you and to your patients.
Consistency without excess - that's the SmartToxin.
FDA approved. Clinically proven.
- Xeomin® is a Botulinum Toxin Type A that blocks transmission of acetylcholine (ACh) from neuron to muscle
- This inhibits muscle contraction and causes muscle paresis (weakness) or paralysis
- Botulinum Toxin Type A only affects “cholinergic neurons” (neurons which use acetylcholine as a neurotransmitter)
- Botulinum Toxin Type A effects dissipate after ~ 3 months because new SNAP-25 proteins take 3 months to be synthesized1
Before and After Xeomin:
Baseline and 30 Day Images
Anna
Aziza
Astrid
Molecule:
Xeomin's Core Neurotoxin
Neurotoxin with Complexing / Unneccessary Proteins
Our precise manufacturing process
The active ingredient of Xeomin is botulinum serotype A. Merz takes the toxin complex and employs a precise manufacturing process that isolates the therapeutic component and removes the complexing/unnecessary proteins to produce Xeomin. Complexing/unnecessary proteins accompany the active neurotoxin but do not play an active role in treatment. Studies have not been performed to determine whether the presence or absence of complexing/unnecessary proteins has a long-term effect on safety or efficacy.
Xpectations Delivered
In 2 randomized, double-blind, multicenter clinical trials, Xeomin was proven to temporarily improve the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.1-3 The most commonly observed adverse reaction incidence ≥2% of patients and greater than placebo) for Xeomin was headache (5.4%).
SIGNIFICANTLY SUPERIOR EFFICACY OVER PLACEBO
In a prospective, multicenter, randomized, double-blind, parallel trial, Xeomin was randomized 1:1 vs another neurotoxin. The study enrolled 250 healthy female patients (≥18 years old) with glabellar lines of at least moderate severity at maximum frown. Xeomin demonstrated comparable efficacy and duration up to four months. Patients were classified as responders only if they had a ≥1 point improvement from the baseline on the Facial Wrinkle Scale (FWS) at maximum frown, as assessed by the independent review panel using subject photographs at one month post treatment.